These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 25515952

  • 1. Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223.
    Nome R, Hernes E, Bogsrud TV, Bjøro T, Fosså SD.
    Scand J Urol; 2015 Jun; 49(3):211-7. PubMed ID: 25515952
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. 68Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with 223Ra: Proof of Concept.
    Ahmadzadehfar H, Azgomi K, Hauser S, Wei X, Yordanova A, Gaertner FC, Kürpig S, Strunk H, Essler M.
    J Nucl Med; 2017 Mar; 58(3):438-444. PubMed ID: 27660148
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.
    Parker CC, Pascoe S, Chodacki A, O'Sullivan JM, Germá JR, O'Bryan-Tear CG, Haider T, Hoskin P.
    Eur Urol; 2013 Feb; 63(2):189-97. PubMed ID: 23000088
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Initial Experience With Radium-223 Chloride Treatment at the Kanazawa University Hospital.
    Nakashima K, Makino T, Kadomoto S, Iwamoto H, Yaegashi H, Iijima M, Kawaguchi S, Nohara T, Shigehara K, Izumi K, Kadono Y, Matsuo S, Mizokami A.
    Anticancer Res; 2019 May; 39(5):2607-2614. PubMed ID: 31092459
    [Abstract] [Full Text] [Related]

  • 11. Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
    Armstrong AJ, Gupta S, Healy P, Kemeny G, Leith B, Zalutsky MR, Spritzer C, Davies C, Rothwell C, Ware K, Somarelli JA, Wood K, Ribar T, Giannakakou P, Zhang J, Gerber D, Anand M, Foo WC, Halabi S, Gregory SG, George DJ.
    PLoS One; 2019 May; 14(5):e0216934. PubMed ID: 31136607
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Relationship of serum prostate-specific antigen and alkaline phosphatase levels with bone metastases in patients with prostate cancer].
    Wang ZL, Wang XF.
    Zhonghua Nan Ke Xue; 2005 Nov; 11(11):825-7. PubMed ID: 16333960
    [Abstract] [Full Text] [Related]

  • 14. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
    Ozu C, Nakashima J, Horiguchi Y, Oya M, Ohigashi T, Murai M.
    Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
    [Abstract] [Full Text] [Related]

  • 15. Impact of pre-treatment variables on the completion of 223radium-dichloride therapy in mCRPC patients with bone metastases.
    Lavelli V, Nappi AG, Caputo P, Asabella AN, Fanelli M, Sardaro A, Altini C, Ferrari C, Rubini G.
    Hell J Nucl Med; 2019 May; 22 Suppl 2():153-163. PubMed ID: 31802056
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase.
    Wymenga LF, Boomsma JH, Groenier K, Piers DA, Mensink HJ.
    BJU Int; 2001 Aug; 88(3):226-30. PubMed ID: 11488734
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.